Fulvestrant

• CAT Number: A000986
• CAS Number: 129453-61-8
• Molecular Formula: C₂₃H₄₇F₅O₃S
• Molecular Weight: 606.77
• Purity: ≥95%
• Synonyms: 129453-61-8; Faslodex; ICI 182,780; Ici 182780; ICI-182780
• Target: Estrogen/progestogen Receptor
• Solubility: >30.3mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
• InChI: InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1
• InChIKey: VWUXBMIQPBEWFH-WCCTWKNTSA-N
• SMILES: CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F

Fulvestrant (CAT: A000986) is a synthetic estrogen receptor antagonist. Unlike tamoxifen (which has partial agonist effects) and aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. This product is used for medical research and development and other scientific research purposes.

Reference

1: Haddad TC, D/'Assoro A, Suman V, Opyrchal M, Peethambaram P, Liu MC, Goetz MP, Ingle JN. Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer. Breast Cancer Res Treat. 2017 Dec 30. doi: 10.1007/s10549-017-4616-7. [Epub ahead of print] PubMed PMID: 29289986.
2: Deeks ED. Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy. Drugs. 2018 Jan;78(1):131-137. doi: 10.1007/s40265-017-0855-5. PubMed PMID: 29270913.
3: du Rusquec P, Palpacuer C, Campion L, Patsouris A, Augereau P, Gourmelon C, Robert M, Dumas L, Caroline F, Campone M, Frenel JS. Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2017 Dec 15. doi: 10.1007/s10549-017-4623-8. [Epub ahead of print] PubMed PMID: 29247442.
4: Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, O/'Regan R, Mouret-Reynier MA, Kalev D, Egle D, Csőszi T, Bordonaro R, Decker T, Tjan-Heijnen VCG, Blau S, Schirone A, Weber D, El-Hashimy M, Dharan B, Sellami D, Bachelot T. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Jan;19(1):87-100. doi: 10.1016/S1470-2045(17)30688-5. Epub 2017 Dec 7. PubMed PMID: 29223745.
5: Blancas I, Fontanillas M, Conde V, Lao J, Martínez E, Sotelo MJ, Jaen A, Bayo JL, Carabantes F, Illarramendi JJ, Gordon MM, Cruz J, García-Palomo A, Mendiola C, Pérez-Ruiz E, Bofill JS, Baena-Cañada JM, Jáñez NM, Esquerdo G, Ruiz-Borrego M. Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice. Clin Transl Oncol. 2017 Nov 24. doi: 10.1007/s12094-017-1797-9. [Epub ahead of print] PubMed PMID: 29178019.
6: Ali JM, Palandri MT, Kallenbach AT, Chavez E, Ramirez J, Onanong S, Snow DD, Kolok AS. Estrogenic effects following larval exposure to the putative anti-estrogen, fulvestrant, in the fathead minnow (Pimephales promelas). Comp Biochem Physiol C Toxicol Pharmacol. 2018 Jan;204:26-35. doi: 10.1016/j.cbpc.2017.10.013. Epub 2017 Nov 6. PubMed PMID: 29122702.
7: Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study. Curr Med Res Opin. 2018 Jan;34(1):49-54. doi: 10.1080/03007995.2017.1400426. Epub 2017 Nov 21. PubMed PMID: 29095648.
8: Hsu PY, Wu VS, Kanaya N, Petrossian K, Hsu HK, Nguyen D, Schmolze D, Kai M, Liu CY, Lu H, Chu P, Vito CA, Kruper L, Mortimer J, Chen S. Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR(+)/HER2(+) Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant. Clin Cancer Res. 2017 Oct 27. doi: 10.1158/1078-0432.CCR-17-1983. [Epub ahead of print] PubMed PMID: 29079660.
9: Sakurai K, Fujisaki S, Kubota H, Hara Y, Suzuki S, Adachi K, Tomita R, Enomoto K, Hirano T, Saga R, Makishima M. [Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Aromatase Inhibitor Resistant Metastatic Breast Cancer]. Gan To Kagaku Ryoho. 2017 Oct;44(10):886-888. Japanese. PubMed PMID: 29066685.
10: Pizzuti L, Natoli C, Gamucci T, Mauri M, Sergi D, Di Lauro L, Paoletti G, Ruggeri E, Iezzi L, Sperduti I, Mentuccia L, Fabbri A, Maugeri-Saccà M, Moscetti L, Barba M, Vici P. Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting. Oncotarget. 2017 Apr 9;8(40):69025-69037. doi: 10.18632/oncotarget.16982. eCollection 2017 Sep 15. PubMed PMID: 28978178; PubMed Central PMCID: PMC5620318.